These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1422320)

  • 1. Effects of ipriflavone on bone mass and calcium metabolism in postmenopausal osteoporosis.
    Agnusdei D; Adami S; Cervetti R; Crepaldi G; Di Munno O; Fantasia L; Isaia GC; Letizia G; Ortolani S; Passeri M
    Bone Miner; 1992 Oct; 19 Suppl 1():S43-8. PubMed ID: 1422320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass.
    Gennari C; Adami S; Agnusdei D; Bufalíno L; Cervetti R; Crepaldi G; Di Marco C; Di Munno O; Fantasia L; Isaia GC; Mazzuoli GF; Ortolani S; Passeri M; Serni U; Vecchiet L
    Calcif Tissue Int; 1997; 61 Suppl 1():S19-22. PubMed ID: 9263612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of 1-year treatment with ipriflavone on bone in postmenopausal women with low bone mass.
    Valente M; Bufalino L; Castiglione GN; D'Angelo R; Mancuso A; Galoppi P; Zichella L
    Calcif Tissue Int; 1994 May; 54(5):377-80. PubMed ID: 8062153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ipriflavone on bone mass in elderly osteoporotic women.
    Passeri M; Biondi M; Costi D; Bufalino L; Castiglione GN; Di Peppe C; Abate G
    Bone Miner; 1992 Oct; 19 Suppl 1():S57-62. PubMed ID: 1422322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of ipriflavone in established osteoporosis and long-term safety.
    Agnusdei D; Bufalino L
    Calcif Tissue Int; 1997; 61 Suppl 1():S23-7. PubMed ID: 9263613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium.
    Melis GB; Paoletti AM; Bartolini R; Tosti Balducci M; Massi GB; Bruni V; Becorpi A; Ottanelli S; Fioretti P; Gambacciani M
    Bone Miner; 1992 Oct; 19 Suppl 1():S49-56. PubMed ID: 1422321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double blind, placebo-controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss.
    Agnusdei D; Crepaldi G; Isaia G; Mazzuoli G; Ortolani S; Passeri M; Bufalino L; Gennari C
    Calcif Tissue Int; 1997 Aug; 61(2):142-7. PubMed ID: 9236262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of ipriflavone in the prevention and treatment of postmenopausal osteoporosis.
    Kovács AB
    Agents Actions; 1994 Mar; 41(1-2):86-7. PubMed ID: 8079827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial.
    Alexandersen P; Toussaint A; Christiansen C; Devogelaer JP; Roux C; Fechtenbaum J; Gennari C; Reginster JY;
    JAMA; 2001 Mar; 285(11):1482-8. PubMed ID: 11255425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years.
    Adami S; Bufalino L; Cervetti R; Di Marco C; Di Munno O; Fantasia L; Isaia GC; Serni U; Vecchiet L; Passeri M
    Osteoporos Int; 1997; 7(2):119-25. PubMed ID: 9166391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of combined low dose of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women.
    Gambacciani M; Ciaponi M; Cappagli B; Piaggesi L; Genazzani AR
    Maturitas; 1997 Sep; 28(1):75-81. PubMed ID: 9391998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design for an ipriflavone multicenter European fracture study.
    Reginster JY; Bufalino L; Christiansen C; Devogelaer JP; Gennari C; Riis BJ; Roux C
    Calcif Tissue Int; 1997; 61 Suppl 1():S28-32. PubMed ID: 9263614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of post-menopausal osteoporosis with recombinant human growth hormone and salmon calcitonin: a placebo controlled study.
    Gonnelli S; Cepollaro C; Montomoli M; Gennari L; Montagnani A; Palmieri R; Gennari C
    Clin Endocrinol (Oxf); 1997 Jan; 46(1):55-61. PubMed ID: 9059558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic and bone effects after administration of ipriflavone and salmon calcitonin in postmenopausal osteoporosis.
    Cecchettin M; Bellometti S; Cremonesi G; Solimeno LP; Torri G
    Biomed Pharmacother; 1995; 49(10):465-8. PubMed ID: 8746073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women.
    Gambacciani M; Spinetti A; Cappagli B; Taponeco F; Felipetto R; Parrini D; Cappelli N; Fioretti P
    J Endocrinol Invest; 1993 May; 16(5):333-7. PubMed ID: 8320424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of ipriflavone--a synthetic derivative of natural isoflavones--on bone mass loss in the early years after menopause.
    Gennari C; Agnusdei D; Crepaldi G; Isaia G; Mazzuoli G; Ortolani S; Bufalino L; Passeri M
    Menopause; 1998; 5(1):9-15. PubMed ID: 9689189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study.
    Morabito N; Crisafulli A; Vergara C; Gaudio A; Lasco A; Frisina N; D'Anna R; Corrado F; Pizzoleo MA; Cincotta M; Altavilla D; Ientile R; Squadrito F
    J Bone Miner Res; 2002 Oct; 17(10):1904-12. PubMed ID: 12369794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of 1-year ipriflavone treatment on lumbar bone mineral density and bone metabolic markers in postmenopausal women with low bone mass.
    Ohta H; Komukai S; Makita K; Masuzawa T; Nozawa S
    Horm Res; 1999; 51(4):178-83. PubMed ID: 10474019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of ipriflavone in postmenopausal women with osteopenia or osteoporosis: A systematic review and meta-analysis.
    Hu Q; Long C; Wu D; You X; Ran L; Xu J; O Klineberg E; Huang S; Chen J; Ning N
    Pharmacol Res; 2020 Sep; 159():104860. PubMed ID: 32407952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New perspectives in the treatment of postmenopausal osteoporosis: ipriflavone.
    Moscarini M; Patacchiola F; Spacca G; Palermo P; Caserta D; Valenti M
    Gynecol Endocrinol; 1994 Sep; 8(3):203-7. PubMed ID: 7847106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.